Ghrelin and GHSs Directly Boost Stress Hormone AVP in Rat Brain Cells
Background
The peptide ghrelin, widely recognized as the "hunger hormone" and a potent growth hormone secretagogue (GHS), plays diverse physiological roles extending beyond appetite regulation, including influencing metabolism, mood, and stress responses. Arginine vasopressin (AVP), a crucial neuropeptide synthesized in the hypothalamus, is fundamental for maintaining fluid balance, regulating blood pressure, and orchestrating the body's neuroendocrine stress axis. While both ghrelin and AVP are implicated in stress physiology, the precise cellular mechanisms by which ghrelin and its synthetic mimetics directly modulate AVP gene expression and peptide release within hypothalamic neurons have remained largely unexplored.
Results
The study revealed a significant and dose-dependent stimulatory effect of ghrelin on AVP production and secretion in hypothalamic cells. Specifically, treatment with ghrelin at a concentration of 100 nM resulted in a robust ~48% increase in AVP mRNA expression compared to untreated control cells (p<0.001), indicating a clear enhancement of gene transcription. Furthermore, ghrelin administration at 1 µM led to a substantial 2.7-fold increase in AVP peptide release into the culture medium over a 24-hour period (p<0.001), demonstrating a direct and potent effect on secretion. The most pivotal finding was that both ghrelin and synthetic GHSs, such as GHRP-6, exerted a powerful dose-dependent stimulatory effect on AVP release, with GHRP-6 showing an impressive 3.5-fold increase at its highest tested concentration (p<0.001). This effect was significantly attenuated by pre-treatment with a specific GHS-R1a antagonist, confirming that these actions are mediated predominantly through the growth hormone secretagogue receptor 1a and establishing a novel signaling pathway.
Why It Matters
This research establishes a critical direct neuroendocrine link between the ghrelin signaling pathway and the regulation of AVP, a key component of the body's stress response system and fluid homeostasis. Understanding how ghrelin and its mimetics directly influence AVP could offer profound insights into the pathophysiology of conditions characterized by AVP dysregulation, such as chronic stress, anxiety disorders, hypertension, and syndrome of inappropriate antidiuretic hormone secretion (SIADH). These findings suggest that targeting the ghrelin/GHS-R1a pathway might represent a novel therapeutic strategy for modulating AVP-related physiological processes or mitigating stress-induced pathologies. Future research should prioritize in vivo studies to confirm these cellular observations in whole organisms and explore the potential for developing highly selective GHS-R1a modulators for clinical applications, potentially moving towards Phase II human trials for specific indications.